CD4+ T cells play distinct roles during the priming versus effector phases of immune checkpoint therapy–dependent tumor elimination by CD8+ T cells
Samuel Ameh(Washington University in St. Louis), Robert D. Schreiber(Parker Institute for Cancer Immunotherapy), Ali H. Ellebedy(Washington University in St. Louis), Derek J. Theisen(Washington University in St. Louis), Aaron J. Schmitz(Washington University in St. Louis), Cora D. Arthur(Washington University in St. Louis), J. Michael White(Washington University in St. Louis), Christopher A. Nelson, Daved H. Fremont(Washington University in St. Louis), Jackson S. Turner(Washington University in St. Louis), Mahima Thapa(Washington University in St. Louis), Kathleen C. F. Sheehan(Washington University in St. Louis), Ruan F. Vieira. Medrano(Washington University in St. Louis), Yuang Song(Washington University in St. Louis), Abhinav Rangarajan(Washington University in St. Louis), Hussein Sultan(Washington University in St. Louis)
Cited by 0
Related Papers
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
|Nature Genetics|2016|1.3k
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
|The Journal of Experimental Medicine|2011|1k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851